Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)

Key Terms

stat6 medical

STAT6 is a protein inside cells that acts like a messenger and switch, carrying signals from the cell surface to turn specific genes on. It is central to immune responses linked to allergies, asthma and some cancers, so changes in STAT6 activity or drugs that affect it can signal potential clinical benefits or risks. Investors watch STAT6 when it appears as a drug target or biomarker because it can influence the value and prospects of therapies in development.

th2 medical

Th2 (T-helper type 2) cells are a subset of immune white blood cells that coordinate antibody-driven responses by releasing chemical signals that tell other immune cells and antibody-producing cells how to react, especially in allergies and certain infections. Investors watch Th2 pathways because many drugs aim to dial these signals up or down to treat asthma, eczema and allergic diseases — think of them as a thermostat companies target to reduce harmful immune overreactions.

ovalbumin medical

Ovalbumin is the main protein found in egg white, commonly used by scientists as a standard test material and as a model allergen in laboratory research. For investors, it matters because products and services that rely on standardized proteins — such as allergy tests, vaccine development tools, quality control for food and biomanufacturing, and certain diagnostics — can drive steady demand, regulatory scrutiny, or supply-chain sensitivity much like a benchmark ingredient in a recipe.

pharmacokinetics medical

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data from the Company’s STAT6 inhibitor program will be presented in four posters at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists (AAI), being held April 15-19, 2026 in Boston, MA.

Details of the presentations are as follows:

Poster Number: 573
Abstract Number: 2257506
Title: Oral STAT6 Inhibitor EPS-3903 Demonstrates Good Preclinical In Vivo Tolerability without Reactive Metabolites or Metabolic/Safety Liabilities
Date: Thursday, April 16, 2026
Time: 11:30 AM – 12:30 PM ET
Session Type: Therapeutic Approaches to Autoimmunity (THER)
Session Title: Therapeutics for Autoimmune Diseases I
Location: Exhibit Hall
Presenter: Jonathan Kibel and Meng Huang, Ph.D.

Poster Number: 193
Abstract Number: 2253997
Title: EPS-3903 Is a Potent and Selective Oral STAT6 Inhibitor that Blocks Th2 Inflammation in an Ovalbumin Asthma Mouse Model
Date: Friday, April 17, 2026
Time: 11:30 AM – 12:30 PM ET
Session Type: Immediate Hypersensitivity, Asthma, and Allergic Responses (HYP)
Session Title: Airway Hypersensitivity and Asthma
Location: Exhibit Hall
Presenter: Yaohui Nie, Ph.D.

Poster Number: 194
Abstract Number: 2257118
Title: Discovery and Characterization of a Potent and Selective Oral Inhibitor of STAT6 for the Treatment of Allergic Diseases
Date: Friday, April 17, 2026
Time: 2:30 – 3:30 PM ET
Session Type: Immediate Hypersensitivity, Asthma, and Allergic Responses (HYP)
Session Title: Airway Hypersensitivity and Asthma
Location: Exhibit Hall
Presenter: Joyce Sweeney Gibbons, Ph.D.

Poster Number: 723
Abstract Number: 2257175
Title: Potent STAT6 Inhibitor EPS-3903 Demonstrates Excellent Preclinical Pharmacokinetics Enabling Sustained STAT6 Inhibition following Once-Daily Oral Dosing in Humans
Date Saturday, April 18, 2026
Time: 11:30 AM – 12:30 PM ET
Session Type: Therapeutic Approaches to Autoimmunity (THER)
Session Title: Therapeutics for Autoimmune Diseases I
Location: Exhibit Hall
Presenter: Daniel Leonard and Tianzhu Zang, Ph.D.

Further information about IMMUNOLOGY2026^TM can be found here. Posters will be available on the Company’s website here following each presentation.

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260316632112/en/

Media and Investors Contact:

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.